

Integrated Assessment of U.S. Marketing Applications: A View into FDA Internal Operations

Amy Bertha Senior Director, Regulatory Policy Regulatory Affairs, Americas Bayer

Disclaimer – Content Slide

The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ("DIA"), its directors, officers, employees, volunteers, members, chapters, councils, Communities or affiliates, or any organization with which the presenter is employed or affiliated.

These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, Drug Information Association Inc., DIA and DIA logo are registered trademarks. All other trademarks are the property of their respective owners.



GLOBAL ANNUAL MEETING

Agenda

Integrated Assessment of Marketing Applications Overview

Rhonda Hearns-Stewart, MD

Associate Director, Implementation for the Integrated Assessment of Marketing Applications, Special Programs

Office of New Drugs, Center for Drug Evaluation and Research

U.S. Food and Drug Administration

Integrated Assessment Process: ORO Regulatory Project Management Perspective

Jennifer Mercier

Director, Office of Regulatory Operations

Office of New Drugs, Center for Drug Evaluation and Research

U.S. Food and Drug Administration



GLOBAL

MFFTING



INMAZEB Case Study: Industry Perspective Janie Parrino, MD

 $\mathsf{D}|\mathsf{A}$

2021

GLOBAL

ANNUAL

Executive Director, Regulatory Affairs Regeneron Pharmaceuticals, Inc.

INMAZEB Case Study: FDA Perspective

John Farley, MD MPH Director, Office of Infectious Diseases Office of New Drugs, Center for Drug Evaluation and Research U.S. Food and Drug Administration

Q&A

Thank You

Amy Bertha

Senior Director, Regulatory Policy Regulatory Affairs, Americas Bayer



